Supplementary protection
LT - Maitanzinoido DM1 konjugatai su antikūnu transtuzumabu, sujungti per neskylantį linkerį, ir jų panaudojimas navikams gydyti
EN - Conjugates of maytansinoid DM1 with antibody trastuzumab, linked through a non-cleavable linker, and its use in the treatment of tumours
SPC
| (11) |
Number of the document |
C 1689846 |
| (68) |
Number of the document |
1689846
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2013 028 |
| (22) |
Date of filing the application |
2013-12-12 |
| (41) |
Date of publication of the application |
2014-01-27 |
|
Date of publication of SPC |
2016-05-25 |
| (24) |
Date of coming into effect of SPC |
2024-10-13 |
Applicant
| (71) |
ImmunoGen, Inc.,
830 Winter Street, Waltham, MA 02451,
US
|
Grantee
| (73) |
ImmunoGen, Inc.,
830 Winter Street, Waltham, MA 02451,
US
|
Attorney or representative
| (74) |
Genė Ona SRUOGIENĖ,
UAB TARPINĖ, A.P.Kavoliuko g. 24-152, LT-04328 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/13/885, 2013-11-19
|
Calculated date of expiry of the SPC
| (94) |
2028-11-19 |
Name of the product protected by the basic patent
| (95) |
Trastuzumabum emtansinum |
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2025-09-16 |
2 |
347.00
EUR
|
Next renewal fee
|
2026-10-13 |
